Safety and tolerability of a 2009 trivalent inactivated split-virion influenza vaccine in infants, children and adolescents

Lambert, Stephen B., Chuk, Lai-man R., Nissen, Michael D., Nolan, Terry M., McVernon, Jodie, Booy, Robert, Heron, Leon, Richmond, Peter C., Walls, Tony, Marshall, Helen S., Reynolds, Graham J., Hartel, Gunter F., Hu, Wilson and Lai, Michael H. (2013) Safety and tolerability of a 2009 trivalent inactivated split-virion influenza vaccine in infants, children and adolescents. Influenza and other Respiratory Viruses, 7 5: 676-685. doi:10.1111/irv.12107


Author Lambert, Stephen B.
Chuk, Lai-man R.
Nissen, Michael D.
Nolan, Terry M.
McVernon, Jodie
Booy, Robert
Heron, Leon
Richmond, Peter C.
Walls, Tony
Marshall, Helen S.
Reynolds, Graham J.
Hartel, Gunter F.
Hu, Wilson
Lai, Michael H.
Title Safety and tolerability of a 2009 trivalent inactivated split-virion influenza vaccine in infants, children and adolescents
Journal name Influenza and other Respiratory Viruses   Check publisher's open access policy
ISSN 1750-2640
1750-2659
Publication date 2013-09-01
Year available 2013
Sub-type Article (original research)
DOI 10.1111/irv.12107
Open Access Status DOI
Volume 7
Issue 5
Start page 676
End page 685
Total pages 10
Place of publication Oxford, United Kingdom
Publisher Wiley-Blackwell
Language eng
Formatted abstract
Objective: To evaluate the safety of CSL's split-virion inactivated trivalent 2009 Southern Hemisphere formulation influenza vaccine (TIV) in children.

Methods: We enrolled 1992 healthy children into three groups: Cohorts A, ≥6 months to <3 years; B, ≥3 years to <9 years; and C, ≥9 years to <18 years. Children received one or two doses of 0·25 ml (22·5 μg haemagglutinin) or 0·5 ml (45 μg) TIV, depending on age and prior vaccination history. We collected post-vaccination solicited adverse event (AE) data (days 0-6), including fever (temperature: ≥37·5°C axilla, ≥38·0°C oral), unsolicited AEs (days 0-29) and serious AEs (SAEs) and new-onset chronic illnesses (NOCIs; to day 180 after last vaccination).

Results: At least one solicited AE was reported by 80%/78%/78% of children in Cohorts A, B and C, respectively. Systemic AEs were more common among Cohort A (72% of participants), and local AEs were more common among Cohort C (71% of participants). Fever was more common in younger cohorts, in influenza vaccine-naïve children (29% of Cohort A receiving their first dose), and following first compared with second doses. Severe fever following a first dose prevented 20 participants receiving their second scheduled vaccine dose. A 7-month-old participant had a single uncomplicated febrile convulsion on the day of vaccination.

Conclusions: Nearly 80% of subjects reported at least one solicited AE following immunization. Fever prevalence was highest in vaccine-naïve Cohort A participants, similar to other paediatric studies using CSL vaccine. Further research to understand fever-related AEs in children following CSL's TIV is recommended.
Keyword Adverse events
Fever
Influenza vaccine
Paediatrics
Safety
Q-Index Code C1
Q-Index Status Confirmed Code
Institutional Status UQ

 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 12 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 13 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Fri, 29 Nov 2013, 04:52:29 EST by System User on behalf of School of Medicine